An infectious disease expert panel cautions against routine use of bamlanivimab (Eli Lilly) and notes that remdesivir (Veklury) can shorten the clinical course of COVID-19 — which could be critical as "as hospitals fill up" across the United States.
The group also said the monoclonal antibodies approved for emergency use by the US Food and Drug Administration (FDA) and still in development hold promise, although more clinical trial data are needed.
These and other recommendations appear in updated guidelines from the Infectious Diseases Society of America (IDSA), released November 18 and 22.
Read more here : https://www.medscape.com/viewarticle/941479#vp_1
Comments